Bristol Myers granted Breakthrough Therapy Designation to izalontamab by FDA

SystImmune and Bristol Myers (BMY) announced that the FDA has granted Breakthrough Therapy Designation to izalontamab brengitecan for the treatment of locally advanced or metastatic non-small cell lung cancer with epidermal growth factor exon 19 deletions or exon 21 L858R substitution mutations whose disease has progressed on or after treatment with an EGFR tyrosine kinase inhibitor and platinum-based chemotherapy.